The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes

Journal of Human Hypertension

Volumn 23, Issue 1, 2009, Pages 48-54

  Mozaffari Khosravi, H ^a   Jalali Khanabadi, B A ^a   Afkhami Ardekani, M ^a   Fatehi, F ^a   Noori Shadkam, M ^b  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Faculty of Engineering   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HIBISCUS SABDARIFFA EXTRACT; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SOUR TEA; SYSTOLIC BLOOD PRESSURE; TEA; THEA NIGRA;

ADULT; ANTIHYPERTENSIVE AGENTS; BEVERAGES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HIBISCUS; HUMANS; HYPERTENSION; LIPID METABOLISM; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; TREATMENT OUTCOME;

EID: 57749204582     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.100     Document Type: Article

References (25)

1. El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Curr Hypertens Rep 2004; 6: 215-223.
2. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
3. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens 2004; 22: 11-19.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-223.
5. Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999-2000. J Hum Hypertens 2002; 16: 305-312.
6. Bahrami H, Sadatsafavi M, Pourshams A, Kamangar F, Nouraei M, Semnani S et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health 2006; 6: 158.
7. Sadeghi M, Roohafza HR, Kelishadi R. Blood pressure and associated cardiovascular risk factors in Iran: Isfahan Healthy Heart Programme. Med J Malaysia 2004; 59: 460-467.
8. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG et al. Hypertension and stroke in Asia: Prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000; 14: 749-763.
9. Ali BH, Al WN, Blunden G. Phytochemical, pharmacological and toxicological aspects of Hibiscus sabdariffa L.: A review. Phytother Res 2005; 19: 369-375.
10. Hirunpanich V, Utaipat A, Morales NP, Bunyapraphatsara N, Sato H, Herunsalee A et al. Antioxidant effects of aqueous extracts from dried calyx of Hibiscus sabdariffa Linn. (Roselle) in vitro using rat low-density lipoprotein (LDL). Biol Pharm Bull 2005; 28: 481-484.
11. Adegunloye BJ, Omoniyi JO, Owolabi OA, Ajagbonna OP, Sofola OA, Coker HA. Mechanisms of the blood pressure lowering effect of the calyx extract of Hibiscus sabdariffa in rats. Afr J Med Med Sci 1996; 25: 235-238.
12. Ali MB, Salih WM, Mohamed AH, Homeida AM. Investigation of the antispasmodic potential of Hibiscus sabdariffa calyces. J Ethnopharmacol 1991; 31: 249-257.
13. Odigie IP, Ettarh RR, Adigun SA. Chronic administration of aqueous extract of Hibiscus sabdariffa attenuates hypertension and reverses cardiac hypertrophy in 2K-1C hypertensive rats. J Ethnopharmacol 2003; 86: 181-185.
14. Onyenekwe PC, Ajani EO, Ameh DA, Gamaniel KS. Antihypertensive effect of roselle (Hibiscus sabdariffa) calyx infusion in spontaneously hypertensive rats and a comparison of its toxicity with that in Wistar rats. Cell Biochem Funct 1999; 17: 199-206.
15. Chen CC, Chou F, Ho WL, Lin WL, Wang CP, Kao S et al. Inhibitory effects of Hibiscus sabdariffa L extract on low-density lipoprotein oxidation and anti-hyperlipidemia in fructose-fed and cholesterol-fed rats. J Sci food and agri 2004; 84: 1989-1996.
16. Herrera-Arellano A, Flores-Romero S, Chavez-Soto MA, Tortoriello J. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: A controlled and randomized clinical trial. Phytomedicine 2004; 11: 375-382.
17. Lin TL, Lin HH, Chen CC, Lin MC, Chou MC, Wang CJ. Hibiscus sabdariffa extract reduces serum cholesterol in men and women. Nutr Res 2007; 27: 140-145.
18. Herrera-Arellano A, Miranda-Sanchez J, vila-Castro P, Herrera-Alvarez S, Jiménez-Ferrer JE, Zamilpa A et al. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril- controlled clinical trial. Planta Med 2007; 73: 6-12.
19. Chen CC, Hsu JD, Wang SF, Chiang HC, Yang MY, Kao ES et al. Hibiscus sabdariffa extract inhibits the development of atherosclerosis in cholesterol-fed rabbits. J Agric Food Chem 2003; 51: 5472-5477.
20. Haji Faraji M, Haji Tarkhani A. The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. J Ethnopharmacol 1999; 65: 231-236.
21. Ajay M, Chai HJ, Mustafa AM, Gilani AH, Mustafa MR. Mechanisms of the anti-hypertensive effect of Hibiscus sabdariffa L. calyces. J Ethnopharmacol 2007; 109: 388-393.
22. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National survey of risk factors for non-communicable diseases of Iran. Diabetes Care 2008; 31: 96-98.
23. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health 2008; 8: 176.
24. Janghorbani M, Amini M. Metabolic syndrome in type 2 diabetes mellitus in isfahan, iran: Prevalence and risk factors. Metab Syndr Relat Disord 2007; 5: 243-254.
25. Anon. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.